The current research in breast cancer vaccination has yet to scratch the surface of potential targets and has mainly focused on oncogenes and peptides such as HER2 and E75 in patients who have already been diagnosed with DCIS or breast cancer. Here, ERBB2 is linked to breast carcinoma.